1
|
Ren Y, Dou W, Wang JJ, Yuan G. Lethal and sublethal effects of fluralaner on the citrus red mite, Panonychus citri (McGregor). PEST MANAGEMENT SCIENCE 2024; 80:3308-3316. [PMID: 38375770 DOI: 10.1002/ps.8034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 02/15/2024] [Accepted: 02/20/2024] [Indexed: 02/21/2024]
Abstract
BACKGROUND The citrus red mite, Panonychus citri (McGregor) is a globally distributed agricultural pest. Of late, resistance to common acaricides has raised concerns that chemical control of P. citri is an inefficient means of control. Fluralaner, a highly toxic isoxazoline insecticide used to treat various ectoparasites, presents one potential alternative. However, little information has been reported about the effect of fluralaner on the citrus red mite. This study aims to evaluate the toxicity, sublethal and transgenerational effects of fluralaner on P. citri. RESULTS In both laboratory and field populations of P. citri, we found fluralaner to be more toxic than conventional alternatives, including fenpropathrin, bifenazate, azocyclotin and chlorpyrifos. Interestingly, fluralaner proved more toxic to female adults than to the eggs of P. citri, with median lethal concentrations (LC50) of 2.446 and 122.7 mg L-1, respectively. Exposure to sublethal concentrations of fluralaner (LC10, LC20 and LC30) significantly reduced the fecundity and longevity of female adults P. citri individuals. Although concentrations of fluralaner applied to the parental female adults (F0) led to some changes in the developmental parameters, there were no significant changes in most of the life table parameters or population growth of the F1 generation. CONCLUSION Our results indicate that fluralaner is highly toxic to P. citri, and a significant sublethal effect on F0 could suppress the population growth of P. citri, but not for F1. Fluralaner may be considered as a pesticide for the future management of the citrus red mite. © 2024 Society of Chemical Industry.
Collapse
Affiliation(s)
- Yiting Ren
- Key Laboratory of Entomology and Pest Control Engineering, College of Plant Protection, Southwest University, Chongqing, China
- Key Laboratory of Agricultural Biosafety and Green Production of Upper Yangtze River (Ministry of Education), Academy of Agricultural Sciences, Southwest University, Chongqing, China
| | - Wei Dou
- Key Laboratory of Entomology and Pest Control Engineering, College of Plant Protection, Southwest University, Chongqing, China
- Key Laboratory of Agricultural Biosafety and Green Production of Upper Yangtze River (Ministry of Education), Academy of Agricultural Sciences, Southwest University, Chongqing, China
| | - Jin-Jun Wang
- Key Laboratory of Entomology and Pest Control Engineering, College of Plant Protection, Southwest University, Chongqing, China
- Key Laboratory of Agricultural Biosafety and Green Production of Upper Yangtze River (Ministry of Education), Academy of Agricultural Sciences, Southwest University, Chongqing, China
| | - Guorui Yuan
- Key Laboratory of Entomology and Pest Control Engineering, College of Plant Protection, Southwest University, Chongqing, China
- Key Laboratory of Agricultural Biosafety and Green Production of Upper Yangtze River (Ministry of Education), Academy of Agricultural Sciences, Southwest University, Chongqing, China
| |
Collapse
|
2
|
Borowski S, Viljoen A, D'Hanis L, Mahabir S, Geurden T. Evaluation of the efficacy of Simparica Trio ® in the prevention of the transmission of Babesia canis by infected Dermacentor reticulatus to dogs. Parasit Vectors 2024; 17:51. [PMID: 38308372 PMCID: PMC10836058 DOI: 10.1186/s13071-023-06115-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 12/27/2023] [Indexed: 02/04/2024] Open
Abstract
BACKGROUND Babesia canis is a clinically relevant vector-borne pathogen in dogs, and its presence is expanding. The efficacy of Simparica Trio® (Zoetis) in the prevention of B. canis transmission was evaluated at the minimum recommended label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel per kg bodyweight. METHODS Twenty-four (24) dogs were randomly allocated to either a placebo-treated group or one of two treatment groups with Simparica Trio. Dogs were infested with B. canis-infected Dermacentor reticulatus ticks 21 or 28 days after treatment administration. Blood samples for antibody and DNA detection were collected from each dog prior to tick infestation until 28 days after infestation. A dog was defined as being B. canis positive if it tested positive by both an indirect immunofluorescence assay (IFA) and PCR at any time during the study. RESULTS No treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFA and PCR. None of the Simparica Trio-treated animals displayed any clinical symptoms or tested positive, resulting in a 100% efficacy in the prevention of canine babesiosis (P < 0.0001). CONCLUSIONS A single treatment with Simparica Trio at the minimum recommended label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel per kg bodyweight prevents the transmission of B. canis by infected D. reticulatus to dogs for at least 28 days.
Collapse
Affiliation(s)
- Stasia Borowski
- Zoetis Belgium SA, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium.
| | - Alta Viljoen
- Clinvet International, Uitzich Road, Bainsvlei, Bloemfontein, 9338, South Africa
| | - Lina D'Hanis
- Zoetis Belgium SA, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium
| | - Sean Mahabir
- Zoetis, Veterinary Medicine Research & Development, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Thomas Geurden
- Zoetis Belgium SA, Veterinary Medicine Research & Development, Mercuriusstraat 20, 1930, Zaventem, Belgium
| |
Collapse
|
3
|
Zygner W, Gójska-Zygner O, Bartosik J, Górski P, Karabowicz J, Kotomski G, Norbury LJ. Canine Babesiosis Caused by Large Babesia Species: Global Prevalence and Risk Factors-A Review. Animals (Basel) 2023; 13:2612. [PMID: 37627403 PMCID: PMC10451873 DOI: 10.3390/ani13162612] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Revised: 07/19/2023] [Accepted: 08/11/2023] [Indexed: 08/27/2023] Open
Abstract
Canine babesiosis is a disease caused by protozoan pathogens belonging to the genus Babesia. Four species of large Babesia cause canine babesiosis (B. canis, B. rossi, B. vogeli, and the informally named B. coco). Although canine babesiosis has a worldwide distribution, different species occur in specific regions: B. rossi in sub-Saharan Africa, B. canis in Europe and Asia, and B. coco in the Eastern Atlantic United States, while B. vogeli occurs in Africa, southern parts of Europe and Asia, northern Australia, southern regions of North America, and in South America. B. vogeli is the most prevalent large Babesia species globally. This results from its wide range of monotropic vector species, the mild or subclinical nature of infections, and likely the longest evolutionary association with dogs. The most important risk factors for infection by large Babesia spp. include living in rural areas, kennels or animal shelters, or regions endemic for the infection, the season of the year (which is associated with increased tick activity), infestation with ticks, and lack of treatment with acaricides.
Collapse
Affiliation(s)
- Wojciech Zygner
- Division of Parasitology and Parasitic Diseases, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences—SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland; (J.B.); (P.G.); (J.K.)
| | - Olga Gójska-Zygner
- Labros Veterinary Clinic, Św. Bonifacego 92, 02-940 Warsaw, Poland; (O.G.-Z.); (G.K.)
| | - Justyna Bartosik
- Division of Parasitology and Parasitic Diseases, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences—SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland; (J.B.); (P.G.); (J.K.)
| | - Paweł Górski
- Division of Parasitology and Parasitic Diseases, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences—SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland; (J.B.); (P.G.); (J.K.)
| | - Justyna Karabowicz
- Division of Parasitology and Parasitic Diseases, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences—SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland; (J.B.); (P.G.); (J.K.)
| | - Grzegorz Kotomski
- Labros Veterinary Clinic, Św. Bonifacego 92, 02-940 Warsaw, Poland; (O.G.-Z.); (G.K.)
| | - Luke J. Norbury
- Department of Biosciences and Food Technology, School of Science, STEM College, RMIT University, Bundoora, VIC 3083, Australia;
| |
Collapse
|
4
|
Chiummo R, Zschiesche E, Capári B, Farkas R, Chiquet M, Rapti D, Postoli R, Audry A, Leschnik M. Field efficacy of fluralaner (Bravecto ® chewable tablets) for preventing Babesia canis infection transmitted by Dermacentor reticulatus ticks to dogs. Parasit Vectors 2023; 16:252. [PMID: 37501160 PMCID: PMC10373369 DOI: 10.1186/s13071-023-05820-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 05/26/2023] [Indexed: 07/29/2023] Open
Abstract
BACKGROUND The isoxazoline fluralaner is effective for prevention of Babesia canis transmission from infected Dermacentor reticulatus ticks to dogs for 84 days in a controlled environment. This study was designed to evaluate the effectiveness of fluralaner chewable tablets for sustained prevention of B. canis infection of dogs in endemic areas under natural conditions. METHODS In Europe, privately owned, clinically healthy pet dogs were enrolled and randomized either to receive fluralaner at 25-56 mg/kg (Bravecto® chewable tablets) on days 0 and 84, or to remain untreated during the D. reticulatus season. Blood samples were collected to evaluate B. canis exposure: on days 0 and 21 (exposure before day 0), during the study and at the end of the tick season (dogs suspected of having become infected after day 0). Efficacy was determined by the percentage reduction in B. canis transmission risk based on the difference in B. canis-positive tests in fluralaner-treated dogs compared with untreated dogs. In addition, ticks collected at monthly intervals throughout the study were identified to species level and females tested for B. canis DNA. RESULTS A total of 152 dogs were enrolled in the study, although nine dogs were excluded because they tested positive for B. canis DNA or antibodies within 21 days after enrollment. During the study period, no fluralaner-treated dog became positive for B. canis, resulting in calculated efficacy of 100%. However, babesiosis infection was diagnosed in five untreated control dogs (Fisher's exact test, left-sided, P = 0.0312). Tick analyses revealed that one sample collected in Hungary was infected with B. canis. CONCLUSION Oral administration of Bravecto chewable tablets at the recommended dosage to dogs completely prevented B. canis transmission under field conditions in an endemic area for 12 weeks.
Collapse
Affiliation(s)
- Rafael Chiummo
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | - Eva Zschiesche
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany
| | | | - Róbert Farkas
- Department of Parasitology and Zoology, University of Veterinary Medicine, Budapest, 1078 Hungary
| | - Mathieu Chiquet
- Artemis Animal Health, 7, rue du Clos Rouillé, Champtocé-sur-Loire, France
| | - Dhimitër Rapti
- Faculty of Veterinary Medicine, Agricultural University of Tirana, Tirana, Albania
| | - Rezart Postoli
- Faculty of Veterinary Medicine, Agricultural University of Tirana, Tirana, Albania
| | - Alain Audry
- Clinique Vétérinaire, 2c Route de Grayan, 33780 Soulac sur Mer, France
| | - Michael Leschnik
- University Clinic for Small Animals, Veterinary University Vienna, Vienna, Austria
| |
Collapse
|
5
|
Weingart C, Helm CS, Müller E, Schäfer I, Skrodzki M, von Samson‐Himmelstjerna G, Krücken J, Kohn B. Autochthonous Babesia canis infections in 49 dogs in Germany. Vet Med (Auckl) 2023; 37:140-149. [PMID: 36629833 PMCID: PMC9889677 DOI: 10.1111/jvim.16611] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 12/08/2022] [Indexed: 01/12/2023]
Abstract
BACKGROUND Vector-borne diseases are of increasing importance in Germany. Since 2015, autochthonous cases have been increasingly documented in Berlin/Brandenburg. OBJECTIVES Describe autochthonous Babesia canis infection in the Berlin/Brandenburg region. ANIMALS Forty-nine dogs with autochthonous B. canis infection. METHODS Evaluation of history, clinical signs, laboratory abnormalities, treatment, and outcome. RESULTS Dogs were presented between March and August (9) and September and January (40) in the years 2015-2021. Historical and clinical findings were lethargy (100%), pale mucous membranes (63%), fever (50%), and pigmenturia (52%). Common clinicopathological findings were thrombocytopenia (100%), anemia (85%), intravascular hemolysis (52%), pancytopenia (41%), and systemic inflammatory response syndrome (SIRS; 37%). Babesia detection was based on blood smear evaluation (n = 40) and PCR targeting the 18S rRNA gene of piroplasms (n = 49). Sequencing indicated 99.47% to 100% identity to B. canis sequences from GenBank. All dogs were treated with imidocarb (2.4-6.3 mg/kg; median, 5 mg/kg); 8 dogs received 1, 35 received 2, and 1 dog each received 3, 4, or 5 injections, respectively. Continued PCR-positive results were detected in 7 dogs after the 1st, in 5 after the 2nd, in 2 after the 3rd, and in 1 28 days after the 4th injection. Four dogs were euthanized and 3 dogs died. CONCLUSIONS AND CLINICAL IMPORTANCE Autochthonous B. canis infections in Berlin/Brandenburg were associated with severe clinicopathological changes, SIRS, and multiorgan involvement. Testing by PCR during and after treatment is advisable to monitor treatment success. Screening of blood donors in high-risk areas and year-round tick protection is strongly recommended.
Collapse
Affiliation(s)
- Christiane Weingart
- Clinic for Small Animals, Faculty of Veterinary MedicineFreie Universität BerlinBerlinGermany
| | - Christina S. Helm
- Institute for Parasitology and Tropical Veterinary MedicineFreie Universität BerlinBerlinGermany
| | | | | | - Marianne Skrodzki
- Clinic for Small Animals, Faculty of Veterinary MedicineFreie Universität BerlinBerlinGermany
| | | | - Jürgen Krücken
- Institute for Parasitology and Tropical Veterinary MedicineFreie Universität BerlinBerlinGermany
| | - Barbara Kohn
- Clinic for Small Animals, Faculty of Veterinary MedicineFreie Universität BerlinBerlinGermany
| |
Collapse
|
6
|
Bonnet SI, Nadal C. Experimental Infection of Ticks: An Essential Tool for the Analysis of Babesia Species Biology and Transmission. Pathogens 2021; 10:pathogens10111403. [PMID: 34832559 PMCID: PMC8620118 DOI: 10.3390/pathogens10111403] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 10/22/2021] [Accepted: 10/26/2021] [Indexed: 11/16/2022] Open
Abstract
Babesiosis is one of the most important tick-borne diseases in veterinary health, impacting mainly cattle, equidae, and canidae, and limiting the development of livestock industries worldwide. In humans, babesiosis is considered to be an emerging disease mostly due to Babesia divergens in Europe and Babesia microti in America. Despite this importance, our knowledge of Babesia sp. transmission by ticks is incomplete. The complexity of vectorial systems involving the vector, vertebrate host, and pathogen, as well as the complex feeding biology of ticks, may be part of the reason for the existing gaps in our knowledge. Indeed, this complexity renders the implementation of experimental systems that are as close as possible to natural conditions and allowing the study of tick-host-parasite interactions, quite difficult. However, it is unlikely that the development of more effective and sustainable control measures against babesiosis will emerge unless significant progress can be made in understanding this tripartite relationship. The various methods used to date to achieve tick transmission of Babesia spp. of medical and veterinary importance under experimental conditions are reviewed and discussed here.
Collapse
Affiliation(s)
- Sarah I. Bonnet
- Animal Health Department, INRAE, 37380 Nouzilly, France
- Functional Genetics of Infectious Diseases Unit, Institut Pasteur, CNRS UMR 2000, Université de Paris, 75015 Paris, France
- Correspondence:
| | - Clémence Nadal
- Epidemiology Unit, Laboratory for Animal Health, University Paris Est, 94700 Maisons-Alfort, France;
- Anses, INRAE, Ecole Nationale Vétérinaire d’Alfort, UMR BIPAR, Laboratoire de Santé Animale, 94700 Maisons-Alfort, France
| |
Collapse
|
7
|
Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. J Vet Pharmacol Ther 2021; 45:1-15. [PMID: 33733534 DOI: 10.1111/jvp.12959] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 02/08/2021] [Accepted: 02/08/2021] [Indexed: 01/01/2023]
Abstract
The isoxazolines are a novel class of ectoparasiticides with potent inhibitory activity on glutamate- and gamma-aminobutyric acid-gated chloride channel located in nervous system of invertebrates. In recent years, studies have been performed to evaluate the efficacy and safety of isoxazolines against various types of ectoparasites, including fleas, ticks, and mites. As more single and combined isoxazoline products have been approved by the United States Food and Drug Administration and European Medicines Agency, a more comprehensive understanding of isoxazolines becomes essential for veterinary clinical practitioners. This article provides a complete review of isoxazolines with respect to pharmacodynamics, pharmacokinetics, ectoparasiticidal efficacy, and safety, which will provide veterinarians information to allow them to make the best choice of ectoparasiticide for their clients' specific needs.
Collapse
Affiliation(s)
- Xueying Zhou
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Alexandra E Hohman
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| | - Walter H Hsu
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
| |
Collapse
|
8
|
Otranto D, Dantas-Torres F, Fourie JJ, Lorusso V, Varloud M, Gradoni L, Drake J, Geurden T, Kaminsky R, Heckeroth AR, Schunack B, Pollmeier M, Beugnet F, Holdsworth P. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) guidelines for studies evaluating the efficacy of parasiticides in reducing the risk of vector-borne pathogen transmission in dogs and cats. Vet Parasitol 2021; 290:109369. [PMID: 33548595 DOI: 10.1016/j.vetpar.2021.109369] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 01/19/2021] [Indexed: 01/04/2023]
Abstract
These guidelines are intended to provide an in-depth review of current knowledge and assist the planning and implementation of studies for evaluating the efficacy of parasiticides in reducing transmission of vector-borne pathogens (VBPs) to dogs and cats. At present, the prevention of VBP transmission in companion animals is generally achieved through the administration of products that can repel or rapidly kill arthropods, thus preventing or interrupting feeding before transmission occurs. The present guidelines complement existing guidelines, which focus on efficacy assessment of parasiticides for the treatment, prevention and control of flea and tick infestations, but also give guidance for studies focused on other vectors (i.e. mosquitoes and phlebotomine sand flies). The efficacy of parasiticides in reducing VBP transmission can be evaluated through laboratory or field studies. As such, the present guidelines provide recommendations for these studies, representing a tool for researchers, pharmaceutical companies and authorities involved in the research, development and registration of products with claims for reducing VBP transmission in dogs and cats, respecting the overall principles of the 3Rs (replacement, reduction and refinement). Gaps in our current understanding of VBP transmission times are herein highlighted and the need for further basic research on related topics is briefly discussed.
Collapse
Affiliation(s)
- Domenico Otranto
- Dipartimento di Medicina Veterinaria, Università degli Studi di Bari, 70010, Valenzano, Italy.
| | - Filipe Dantas-Torres
- Dipartimento di Medicina Veterinaria, Università degli Studi di Bari, 70010, Valenzano, Italy; Department of Immunology, Aggeu Magalhães Institute (Fiocruz-PE), Pernambuco, Brazil
| | | | - Vincenzo Lorusso
- Global Research and Intellectual Property, Vetoquinol, 37 Rue de la Victoire, 75009, Paris, France; School of Science, Engineering and Environment, Peel Building, University of Salford, Greater Manchester, M5 4WT, United Kingdom
| | | | - Luigi Gradoni
- Unit of Vector-Borne Diseases, Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy
| | - Jason Drake
- Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA
| | - Thomas Geurden
- Zoetis, Veterinary Medicine Research and Development, Hoge Wei 10, B-1930, Zaventem, Belgium
| | - Ronald Kaminsky
- ParaC-Consulting for Parasitology and Drug Discovery, 79685, Haeg-Ehrsberg, Germany
| | - Anja R Heckeroth
- MSD Animal Health Innovation GmbH, Zur Propstei, 55270, Schwabenheim, Germany
| | - Bettina Schunack
- Bayer Animal Health GmbH: an Elanco Animal Health Company, 51368, Leverkusen, Germany
| | - Matthias Pollmeier
- Bayer Animal Health GmbH: an Elanco Animal Health Company, 51368, Leverkusen, Germany
| | - Frédéric Beugnet
- Boehringer-Ingelheim Animal Health, 29 Av Tony Garnier, Lyon, 69007, France
| | - Peter Holdsworth
- PAH Consultancy Pty Ltd, Wanniassa, 2903, Canberra, ACT, Australia
| |
Collapse
|
9
|
Prevention of transmission of Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum by Ixodes spp. ticks to dogs treated with the Seresto® collar (imidacloprid 10% + flumethrin 4.5%). Parasitol Res 2019; 119:299-315. [PMID: 31734862 PMCID: PMC6942034 DOI: 10.1007/s00436-019-06394-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 07/05/2019] [Indexed: 11/02/2022]
Abstract
The capability of imidacloprid 10% + flumethrin 4.5% (Seresto®) collars to prevent transmission of Borrelia burgdorferi sensu lato (Bbsl) and Anaplasma phagocytophilum (Ap) by naturally infected ticks was evaluated in two studies with 44 dogs. In each study, one group served as non-treated control, whereas the other groups were treated with the Seresto® collar. All dogs were exposed to naturally Bbsl- and Ap-infected hard ticks (Ixodes ricinus, Ixodes scapularis). In study 1, tick infestation was performed on study day (SD) 63 (2 months post-treatment [p.t.]); in study 2, it was performed on SD 32 (one month p.t.) respectively SD 219 (seven months p.t.). In situ tick counts were performed 2 days after infestation. Tick counts and removals followed 6 (study 1) or 5 days (study 2) later. Blood sampling was performed for the detection of specific Bbsl and Ap antibodies and, in study 1, for the documentation of Ap DNA by PCR. Skin biopsies were examined for Bbsl by PCR and culture (only study 1). The efficacy against Ixodes spp. was 100% at all time points. In study 1, two of six non-treated dogs became infected with Bbsl, and four of six tested positive for Ap; none of the treated dogs tested positive for Bbsl or Ap. In study 2, ten of ten non-treated dogs became infected with Bbsl and Ap; none of the treated dogs tested positive for Bbsl or Ap; 100% acaricidal efficacy was shown in both studies. Transmission of Bbsl and Ap was successfully blocked for up to 7 months.
Collapse
|
10
|
Fourie JJ, Evans A, Labuschagne M, Crafford D, Madder M, Pollmeier M, Schunack B. Transmission of Anaplasma phagocytophilum (Foggie, 1949) by Ixodes ricinus (Linnaeus, 1758) ticks feeding on dogs and artificial membranes. Parasit Vectors 2019; 12:136. [PMID: 30909972 PMCID: PMC6434881 DOI: 10.1186/s13071-019-3396-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 03/11/2019] [Indexed: 11/16/2022] Open
Abstract
Background The interplay of speed of activity of acaricidal products and tick-borne pathogen transmission time is the major driver for disease prevention. This study aimed to investigate the time required for transmission of Anaplasma phagocytophilum by adult Ixodes ricinus ticks in vivo on dogs, and to confirm the time required for transmission observed in vivo, in vitro. Methods Nymphs of I. ricinus were experimentally infected with an A. phagocytophilum strain of canine origin. Dogs were allocated to 6 groups of 3 dogs each. Groups 1–5 were infested with 50 A. phagocytophilum-infected female adult ticks on Day 0. Ticks were removed post-infestation at 3, 6, 12, 24 and 48 h. Dogs in Group 6 were infested with 60 A. phagocytophilum-infected female adult ticks (left on dogs until engorged). Dogs were observed daily for general health and clinically examined on Day 0, and weekly from Day 14. Blood was collected for qPCR and serological analysis on Day 0 (pre-challenge) and weekly thereafter. In the in vitro study each artificial feeding chamber was seeded with 10 adult ticks (5 male/5 female), attachment assessed, and blood pools sampled for qPCR at 6 h intervals up to 72 h after first tick attachment. Results Anaplasma phagocytophilum specific antibodies and DNA were detected in all 3 dogs in Group 6. No A. phagocytophilum-specific antibodies or DNA were detected in any dogs in Groups 1–5. All dogs remained healthy. Female tick attachment in 60 artificial feeding chambers over 72 h ranged between 20–60%. Anaplasma phagocytophilum DNA was detected in the blood collected from 5% of chambers sampled at 6 h, with the highest number of positive samples (16.3%) observed at 36 h. Conclusions Transmission of A. phagocytophilum by I. ricinus ticks starts within a few hours after attachment but establishment of infections in dogs is apparently dependent on a minimum inoculation dose that was only observed when ticks attached for greater than 48 h. These findings highlight the need for acaricidal products to exert a repellent and/or rapid killing effect on ticks to forestall transmission and subsequent disease.
Collapse
|
11
|
Fourie JJ, de Vos C, Crafford D, Pollmeier M, Schunack B. A study on the long-term efficacy of Seresto® collars in preventing Babesia canis (Piana & Galli-Valerio, 1895) transmission to dogs by infected Dermacentor reticulatus (Fabricius, 1794) ticks. Parasit Vectors 2019; 12:139. [PMID: 30902104 PMCID: PMC6431040 DOI: 10.1186/s13071-019-3393-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 03/08/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND An imidacloprid/flumethrin collar (Seresto®) was previously shown to prevent infection with Babesia canis, transmitted by Dermacentor reticulatus, in dogs for up to 1 month after application. The present study evaluated the prevention of transmission throughout the claimed efficacy period of 8 months. METHODS Eight animals each were randomly included in groups 1 (negative control) and 2 (Seresto® collar), respectively. Animals in group 2 received the Seresto® collar on Day 0. Tick challenges were performed monthly from the 2nd to the 8th month. Assessment criteria included in situ tick counts 48 hours post-challenge, polymerase chain reaction (PCR) analyses and immunofluorescence assays (IFA). Whenever dogs were diagnosed with babesiosis they were "rescue-treated", excluded and replaced. Consequently, 24 replacement animals were introduced at various time points throughout the study in the control group; thus data for a total of 32 dogs were available in the latter group at study termination. RESULTS Acaricidal efficacy for in situ counts was 93% on Day 30, and ranged from 97 to 100% thereafter. No B. canis specific DNA or antibodies were detected in any Seresto®-treated dog at any time. Babesia canis-specific DNA and antibodies were detected in 2-6 of 8 control dogs after each challenge, confirming the validity of the challenge model. CONCLUSIONS The Seresto® collar was highly effective against challenges with D. reticulatus ticks for up to 8 months. The high sustained acaricidal efficacy over this period prevented transmission of B. canis, thus fully protecting dogs against infection in this experimental infestation model.
Collapse
Affiliation(s)
- Josephus J. Fourie
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa
| | - Christa de Vos
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa
| | - Dionne Crafford
- Clinvet International (Pty) Ltd, Uitzich Road, Bainsvlei, Bloemfontein, South Africa
| | | | | |
Collapse
|
12
|
Lavan R, Tunceli K, de Swardt H, Chelchinskey C, Abatzidis M, Armstrong R. Canine babesiosis treatment rates in South African veterinary clinics between 2011 and 2016. Parasit Vectors 2018; 11:386. [PMID: 29970141 PMCID: PMC6029134 DOI: 10.1186/s13071-018-2962-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Accepted: 06/19/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND South African veterinarians report the perception of a multi-year decline in the number of dogs presenting with clinical babesiosis, a common and serious disease of dogs in the country. This study tested this observation through analysis of veterinary hospital medical records from 2011 through 2016. METHODS Medical records were collected from 44 participating South African veterinary hospitals. The collected medical records were searched to enumerate the number of Babesia-specific medication treatments administered to dogs at all participating hospitals. A healthcare use rate was calculated for canine babesiosis treatment for each calendar year from 2011 to 2016. The healthcare use rate numerator was the total number of canine babesiosis treatments and the denominator was the total dog visits to all participating veterinary practices over the same period. RESULTS There were 2.6 million dog visits to 44 participating veterinary practices between 2011 and 2016. The number of canine babesiosis treatments for each year in chronological order starting with 2011 was: 2957; 2679; 2456; 2746; 2272; and 1592. South African regions with the highest number of canine babesiosis treatments were Gauteng, Free State and Mpumalanga. The overall calculated healthcare use rate for canine babesiosis treatment declined 72% over the study period from 1.18% in 2011 to 0.33% in 2016. The steepest decline of 31% was observed between 2015 and 2016. CONCLUSIONS South African veterinary practices saw a decline in canine babesiosis treatment administration from 2011 to 2016 with the steepest decline beginning in 2015.
Collapse
Affiliation(s)
- Robert Lavan
- Outcomes Research, Animal Health, Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, NJ USA
| | - Kaan Tunceli
- Outcomes Research, Animal Health, Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, NJ USA
| | - Hendrik de Swardt
- Otomys Software Solutions CC, PO Box 904 287, Faerie Glen, 0043 South Africa
| | | | - Mats Abatzidis
- MSD Animal Health, 20 Spartan Road, Spartan, Kempton Park, 1619 South Africa
| | - Rob Armstrong
- MSD Animal Health, 2 Giralda Farms, Madison, NJ 07940 USA
| |
Collapse
|
13
|
Arthropod-borne pathogens of dogs and cats: From pathways and times of transmission to disease control. Vet Parasitol 2017; 251:68-77. [PMID: 29426479 DOI: 10.1016/j.vetpar.2017.12.021] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Revised: 12/25/2017] [Accepted: 12/26/2017] [Indexed: 11/21/2022]
Abstract
Vector-borne pathogens have developed a close relationship with blood feeding arthropod ectoparasites (e.g., mosquitoes, ticks, phlebotomine sand flies, black flies, fleas, kissing bugs, lice) and exploited a huge variety of vector transmission routes. Therefore, the life cycles of these pathogens result in a long evolved balance with the respective arthropod biology, ecology and blood feeding habits, instrumentally to the infection of several animal species, including humans. Amongst the many parasite transmission modes, such as ingestion of the arthropod, with its faeces or secretions, blood feeding represents the main focus for this article, as it is a central event to the life of almost all arthropod vectors. The time frame in which pathogens are transmitted to any animal host is governed by a large number of biological variables related to the vector, the pathogen, the host and environmental factors. Scientific data available on transmission times for each pathogen are discussed relative to their impact for the success of vector-borne disease control strategies. Blocking pathogen transmission, and thus preventing the infection of dogs and cats, may be achievable by the use of chemical compounds if they are characterised by a fast onset of killing activity or repellence against arthropods. The fast speed of kill exerted by systemic isoxazoline, as well as the repellent effect of pyrethroids have renewed the interest of the scientific community and pharmaceutical companies towards reducing the burden of vector-borne diseases under field conditions. However, endosymbionts and vaccines targeting arthropods or pathogen antigens should be further investigated as alternative strategies towards the goal of achieving an effective integrated control of vector-borne diseases.
Collapse
|
14
|
Geurden T, Six R, Becskei C, Maeder S, Lloyd A, Mahabir S, Fourie J, Liebenberg J. Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs. Parasit Vectors 2017; 10:415. [PMID: 28877743 PMCID: PMC5588728 DOI: 10.1186/s13071-017-2358-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Accepted: 08/30/2017] [Indexed: 11/17/2022] Open
Abstract
Background Canine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated in twenty-four dogs randomly allocated to either a placebo-treated group or one of two sarolaner-treated groups. At 21 or 28 days after treatment administration, dogs were infested with 50 ± 4 Dermacentor reticulatus ticks of which 25% were confirmed to be infected with Babesia canis. Blood samples were collected from each dog prior to tick infestation and weekly thereafter until 49 days after infestation. The blood was assayed for B. canis antibodies using an indirect immunofluorescence test (IFAT) and for B. canis DNA by PCR assay. A dog was a priori defined as B. canis-positive if it tested positive by both IFAT and PCR at any time during the study. Results No treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFAT and PCR. None of the sarolaner-treated animals displayed any clinical symptoms or tested positive on both IFAT and PCR, resulting in a 100% efficacy in the prevention of canine babesiosis (P = 0.0002). Conclusion When given 21 or 28 days before tick infestation, a single treatment with sarolaner at the minimum recommended label dose of 2.0 mg per kg body weight prevented the transmission of B. canis by D. reticulatus to dogs.
Collapse
Affiliation(s)
| | - Robert Six
- Zoetis, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | | | - Steven Maeder
- Zoetis, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Anne Lloyd
- Zoetis, Mercuriusstraat 20, B-1930, Zaventem, Belgium
| | - Sean Mahabir
- Zoetis, 333 Portage Street, Kalamazoo, MI, 49007, USA
| | - Josephus Fourie
- Clinvet International, PO Box 11186, 9321, Uitsig Road, Universitas, Bloemfontein, 9338, South Africa
| | - Julian Liebenberg
- Clinvet International, PO Box 11186, 9321, Uitsig Road, Universitas, Bloemfontein, 9338, South Africa
| |
Collapse
|
15
|
Schorderet-Weber S, Noack S, Selzer PM, Kaminsky R. Blocking transmission of vector-borne diseases. Int J Parasitol Drugs Drug Resist 2017; 7:90-109. [PMID: 28189117 PMCID: PMC5302141 DOI: 10.1016/j.ijpddr.2017.01.004] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 01/22/2017] [Indexed: 12/16/2022]
Abstract
Vector-borne diseases are responsible for significant health problems in humans, as well as in companion and farm animals. Killing the vectors with ectoparasitic drugs before they have the opportunity to pass on their pathogens could be the ideal way to prevent vector borne diseases. Blocking of transmission might work when transmission is delayed during blood meal, as often happens in ticks. The recently described systemic isoxazolines have been shown to successfully prevent disease transmission under conditions of delayed pathogen transfer. However, if the pathogen is transmitted immediately at bite as it is the case with most insects, blocking transmission becomes only possible if ectoparasiticides prevent the vector from landing on or, at least, from biting the host. Chemical entities exhibiting repellent activity in addition to fast killing, like pyrethroids, could prevent pathogen transmission even in cases of immediate transfer. Successful blocking depends on effective action in the context of the extremely diverse life-cycles of vectors and vector-borne pathogens of medical and veterinary importance which are summarized in this review. This complexity leads to important parameters to consider for ectoparasiticide research and when considering the ideal drug profile for preventing disease transmission.
Collapse
Affiliation(s)
| | - Sandra Noack
- Boehringer Ingelheim Animal Health GmbH, Binger Str. 173, 55216 Ingelheim, Germany.
| | - Paul M Selzer
- Boehringer Ingelheim Animal Health GmbH, Binger Str. 173, 55216 Ingelheim, Germany.
| | - Ronald Kaminsky
- ParaC Consulting for Parasitology and Drug Discovery, Altenstein 13, 79685 Haeg-Ehrsberg, Germany.
| |
Collapse
|